Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
How comfort foods trigger pleasure in our brains - 2This Week In Space podcast: Episode 186 — Snow on the Moon?
- 310 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- 4Artemis II updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- 5Thousands of Walgreens nasal spray bottles recalled. See which ones.
- Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- Space station changes command, setting stage for Crew 11 departure
- Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- Support Your Investment funds with These Individual accounting Thoughts
- Monetary Security: Building Serious areas of strength for an Establishment
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
